Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1935 2
1936 1
1940 1
1946 1
1947 2
1948 3
1950 1
1961 5
1962 2
1963 2
1964 4
1965 2
1966 4
1967 1
1968 2
1969 2
1970 3
1971 2
1972 2
1973 1
1974 3
1975 3
1976 1
1977 4
1978 3
1979 1
1980 1
1981 1
1982 5
1985 4
1986 5
1987 5
1988 10
1989 15
1990 15
1991 19
1992 24
1993 19
1994 29
1995 14
1996 34
1997 23
1998 34
1999 42
2000 46
2001 65
2002 71
2003 93
2004 117
2005 153
2006 174
2007 205
2008 220
2009 278
2010 309
2011 377
2012 405
2013 461
2014 435
2015 472
2016 498
2017 562
2018 550
2019 527
2020 580
2021 570
2022 436
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

7,021 results
Results by year
Filters applied: . Clear all
Page 1
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
Horn L, Wang Z, Wu G, Poddubskaya E, Mok T, Reck M, Wakelee H, Chiappori AA, Lee DH, Breder V, Orlov S, Cicin I, Cheng Y, Liu Y, Fan Y, Whisenant JG, Zhou Y, Oertel V, Harrow K, Liang C, Mao L, Selvaggi G, Wu YL. Horn L, et al. Among authors: lee dh. JAMA Oncol. 2021 Nov 1;7(11):1617-1625. doi: 10.1001/jamaoncol.2021.3523. JAMA Oncol. 2021. PMID: 34473194 Free PMC article. Clinical Trial.
Consensus for HER2 alterations testing in non-small-cell lung cancer.
Ren S, Wang J, Ying J, Mitsudomi T, Lee DH, Wang Z, Chu Q, Mack PC, Cheng Y, Duan J, Fan Y, Han B, Hui Z, Liu A, Liu J, Lu Y, Ma Z, Shi M, Shu Y, Song Q, Song X, Song Y, Wang C, Wang X, Wang Z, Xu Y, Yao Y, Zhang L, Zhao M, Zhu B, Zhang J, Zhou C, Hirsch FR. Ren S, et al. Among authors: lee dh. ESMO Open. 2022 Feb;7(1):100395. doi: 10.1016/j.esmoop.2022.100395. Epub 2022 Feb 8. ESMO Open. 2022. PMID: 35149428 Free PMC article. Review.
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆.
Niu J, Maurice-Dror C, Lee DH, Kim DW, Nagrial A, Voskoboynik M, Chung HC, Mileham K, Vaishampayan U, Rasco D, Golan T, Bauer TM, Jimeno A, Chung V, Chartash E, Lala M, Chen Q, Healy JA, Ahn MJ. Niu J, et al. Among authors: lee dh. Ann Oncol. 2022 Feb;33(2):169-180. doi: 10.1016/j.annonc.2021.11.002. Epub 2021 Nov 18. Ann Oncol. 2022. PMID: 34800678 Free article. Clinical Trial.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Cho BC, et al. Among authors: lee dh. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
The Law Changes Behaviors: Is It Just Enough?
Lee DH. Lee DH. Cancer Res Treat. 2021 Oct;53(4):895-896. doi: 10.4143/crt.2021.1025. Epub 2021 Sep 23. Cancer Res Treat. 2021. PMID: 34583459 Free PMC article. No abstract available.
7,021 results